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SUMMARY
By misdirecting the activity of Activation-Induced Deaminase (AID) to a conditionalMYC transgene, we have
achieved sporadic, AID-dependentMYC activation in germinal center B cells of Vk*MYCmice. Whereas con-
trol C57BL/6 mice develop benign monoclonal gammopathy with age, all Vk*MYC mice progress to an indo-
lent multiple myeloma associated with the biological and clinical features highly characteristic of the human
disease. Furthermore, antigen-dependent myeloma could be induced by immunization with a T-dependent
antigen. Consistent with these findings in mice, more frequent MYC rearrangements, elevated levels of
MYC mRNA, and MYC target genes distinguish human patients with multiple myeloma from individuals
with monoclonal gammopathy, implicating a causal role for MYC in the progression of monoclonal gammo-
pathy to multiple myeloma.INTRODUCTION
Cancer cells acquire multiple somatic mutations, with the ulti-
mate tumor phenotype critically dependent upon both the iden-
tity of the mutated genes and the precise timing at which these
mutations occur during cellular development. Mouse models
have sought to faithfully reproduce these events but have been
limited by their inability to simultaneously recapitulate the pre-
cise timing, tissue specificity, and sporadic nature of the onco-
genic events, in which a single cell randomly acquires a mutation
that predisposes it to become transformed in a field of normalcells (Rangarajan and Weinberg, 2003). Several conditional ex-
pression systems allow the fine control of gene expression in a
tissue- and developmental stage-specific manner (e.g., through
tet regulation, tamoxifen induction, cre-mediated recombina-
tion, or TVA-mediated viral infection); however, none of these
are sporadic, as they still produce a lawn ofmutant cells (Jonkers
and Berns, 2002). In an elegant and uniquemurine model of spo-
radic oncogene activation, a mutant K-ras allele is somatically
activated by spontaneous recombination in single cells, resulting
in the development of both lung tumors and T cell lymphomas
(Johnson et al., 2001). However, in this model it has not beenSIGNIFICANCE
Twenty-five years after MYC chromosomal translocations were identified in lymphoma, a causative role for MYC dysregu-
lation in mature B cell malignancy has finally been established. In previous studies, forced expression ofMYC in transgenic
mice invariably led to pre-germinal center lymphomas. By hijacking the somatic hypermutation machinery, which is impli-
cated in the development ofMYC chromosomal translocations, we achieved sporadic, AID-dependent activation ofMYC in
the germinal center, uncovering a role forMYC in the development ofmultiplemyeloma inmice. Togetherwith the analysis of
the expression ofMYC andMYC target genes in humanmyeloma, these results indicate thatMYC dysregulation can induce
the progression of a benign monoclonal gammopathy to a fully malignant multiple myeloma.
Cancer Cell 13, 167–180, February 2008 ª2008 Elsevier Inc. 167
Cancer Cell
Myeloma Induced by Activation of MYC Transgenepossible to direct the oncogenic event to a given cell type, or
a specific time in cellular development.
B cell neoplasms offer a unique advantage in studying tumor
development, as their initiating oncogenic events can be related
to precisely timed physiologic DNA rearrangements and muta-
tions occurring at the immunoglobulin (Ig) loci. The Ig genes of
activated B cells in the germinal center (GC) undergo somatic
hypermutation (SHM) and class switch recombination (CSR), re-
sulting in receptors with higher affinity for antigen and enhanced
effector function (MacLennan, 1994; McHeyzer-Williams and
McHeyzer-Williams, 2005). DNA breaks introduced during these
physiologic processes have been postulated to predispose to
chromosome translocations in diffuse large B cell lymphoma
(DLBCL), Burkitt’s lymphoma (BL), multiple myeloma (MM),
and mouse plasmacytoma (MPC) (Bergsagel and Kuehl, 2001;
Gabrea et al., 1999; Kuppers, 2005). Both SHM and CSR re-
quire the activity of Activation-Induced Deaminase (AID), whose
enzymatic activity has already been linked to IgH/MYC translo-
cations and oncogene mutations (Kotani et al., 2007; Ramiro
et al., 2004).
Although MYC was identified 25 years ago as the oncogene
dysregulated by Ig translocations in BL (Dalla-Favera et al.,
1983), MPC (Shen-Ong et al., 1982), and rat immunocytomas
(Pear et al., 1988), and by complex translocations in human
MM (Avet-Loiseau et al., 2007; Shou et al., 2000), no models
have to date convincingly recreated these GC/post-GC disease
entities in a mouse. Instead, previous models of forced MYC
expression mediated by Ig regulatory elements, whose activity
initiates in pre-GC B cells, invariably produced pre-GC lympho-
mas or PC neoplasms lacking significant (>2%) evidence of Ig
SHM (Adams et al., 1985; Cheung et al., 2004; Janz, 2006; Koval-
chuk et al., 2000; Palomo et al., 1999; Park et al., 2005).
To map sporadic oncogene activation specifically to the GC,
we generated transgenic mice in which the activation of MYC,
under the control of the kappa light chain gene regulatory
elements, occurs sporadically through the exploitation of the
physiological SHM process in GC B cells. Strikingly, while BL
was observed in 2/122 cases only, Vk*MYC mice universally de-
veloped post-GC PC tumors that fully recapitulate the biological
and clinical features of human MM.
RESULTS
Generation of Matching Vk-MYC and Vk*MYC Mice
We previously generated a vector (Vk-MYC [Robbiani et al.,
2005]) with a V-kappa exon splicing in-frame to the coding
portion of the genomic locus of human MYC (exons 2 and 3), in
which the intron-exon structure and polyadenylation signal
were maintained, but the first methionine (Met) for initiation of
translation was removed. An almost identical vector, Vk*MYC,
was generated in which the third codon of the V-kappa exon,
TCG, was mutated to a stop codon TAG (Figure 1A). In this
Vk*MYC construct, transcription was predicted to occur as in
the Vk-MYC vector; however, translation would prematurely
abort because of the engineered stop codon, and MYC protein
would not be expressed. This stop codon created a DGYWmotif
that represents a known preferential target sequence for SHM
(Rogozin and Diaz, 2004). We hypothesized that in B cells under-
going SHM the same mechanism would also introduce muta-
168 Cancer Cell 13, 167–180, February 2008 ª2008 Elsevier Inc.tions in the transgenic locus, which contains all of the IgK light
chain regulatory elements required for targeting by SHM (Betz
et al., 1994; Papavasiliou and Schatz, 2000), and sporadically re-
vert the stop codon allowing activation of MYC translation.
Transfection experiments in 293T cells confirmed that translation
of MYC was completely aborted in the presence of the engi-
neered stop codon and did not initiate from downstream AUG
(Figure 1B and Figure S1). Vk*MYC mice were generated by mi-
croinjection into C57BL/6 oocytes, and two independent
founders were obtained, MYC11 and -24, with 20 and 8 copies
of the transgene, respectively (Figure 1C). The kappa promoter
and enhancers are active in B cells, beginning at the pro-B stage,
but their activity strongly increases with plasma cell (PC) differ-
entiation (Fulton and Van Ness, 1993). Among multiple tissues
analyzed, transgenic mRNA expression was detectable only in
spleen and bone marrow (BM) and was markedly upregulated
upon LPS stimulation to induce PC differentiation (Figure 1D
and Figure S2).
Vk*MYC Mice Develop Monoclonal PC Expansion
Constitutive MYC expression in early B cells of Vk-MYC mice
led to a very aggressive pro-B lymphoma, consistent with the
reported phenotype of the Em-myc transgenic mice (Adams
et al., 1985; Robbiani et al., 2005). Introduction of an engineered
stop codon in Vk*MYC ORF completely abolished this pheno-
type. The two lines of Vk*MYC mice (-11 and -24) behaved iden-
tically. At a young age their phenotype was indistinguishable
from that of WT littermates (data not shown). With age, however,
100% of the 122 mice analyzed developed a slowly progressive
monoclonal expansion of PCs restricted to the BM, reminiscent
of human MM (Kuehl and Bergsagel, 2002). IHC staining of BM
sections from aged Vk*MYC, but not wild-type (WT), mice
showed multiple foci of PCs in which all the CD138-positive
PCs are stained with nuclear MYC, indicating activation of the
transgene (Figure 2A). PCs in Vk*MYC mice, as in human MM
and in contrast to MPC, were mainly not proliferative, with only
a minority costaining with CD138+ and Ki67+(Figure 2A, bottom
panel). This is not unexpected, despite the fact that MYC ex-
pression has been often associated with strong proliferative
activity: quiescent mantle zone and marginal zone B cells, but
not proliferating GC cells, express MYC message (Klein et al.,
2003) as well as MYC protein in a subset of human marginal
zone cells with a memory phenotype (G.C., unpublished data).
Flow cytometry (FCM) on BM and secondary lymphoid organs
demonstrated that Vk*MYC mice accumulate terminally differ-
entiated PCs (CD138+B220) exclusively in the BM and not in
spleen or lymph nodes (Figure 2B). On average the BM PC
content by FCM was 12%, with a range of 2%–62%, and
approximately 80% of necropsied mice had more then 5%
BM PCs.
A feature of MM and other PC neoplasia is the secretion of
a large amount of monoclonal antibodies that can be detected
in the serum as a distinct band (M-spike) by Serum Protein Elec-
trophoresis (SPEP) (Longsworth et al., 1939). M-spikes were de-
tectable starting at 20 weeks of age in Vk*MYC mice, with their
intensity progressing over time, often surpassing that of albumin
(Figures 2C and 2D). In most of the mice the PC expansion was
monoclonal: out of 85 mice with M-spikes, 70% had a single
sharp monoclonal spike, 16% had two, 6% had three, and 8%
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Matching Vk- and Vk*MYC Mice
(A) Schematic representation of the Vk-MYC and
Vk*MYC vectors. Displayed is a rearranged Vk21
gene in which the Jk5 exon has been replaced
by a short coding exon containing a Kozak ATG,
and the Ck region has been replaced by a genomic
portion of human MYC (exons 2 and 3). Trans-
cription initiates at the Vk21E proximal promoter
(arrow), extends to the leader (L) and Vk (V) exons,
splices in frame to hMYC, and terminates at the
endogenous polyA signal (shown). Open and
black boxes represent noncoding and coding
exons, respectively, including MYC exons 2
and 3. Diagram is not drawn to scale. Asterisks
show ATG codons in the leader (L) exon mutated
into ACG to avoid premature initiation of trans-
lation. The spatial configuration of the Vk locus
has been maintained, and the open circles indi-
cate the two regulatory regions: intronic enhancer
(ie) and 30 kappa enhancer (30kE). In the ORF
closeup panel is shown the nucleotide and amino
acid sequence of the first coding exon: the
initiation of translation ATG; the TCG > TAG mu-
tated stop codon is boxed, and the DGYW
(AGTA) nucleotide sequence, hot spot for SHM,
is underlined.
(B) Only CMV but not CMV* constructs express
a transgenic MYC protein. 293T cells have been
transfected with CMV*- and CMV-MYC con-
structs, in which the Vk promoter has been re-
placed by the CMV promoter active in 293T. Total
proteins have been analyzed by western blot for
humanMYC (upper) and b-actin (lower). The lower
bands in the MYC blot represent the endogenous
MYC protein expressed by 293T cells.
(C) Southern blot on tail DNA from Vk*MYC
founders identify 20 and 8 transgene copies in
Vk*MYC11 and -24, respectively (lower bands). Top
bands represent the endogenous 30kE locus. The transgene integration site is detected in the Vk*MYC24 founder (middle band).
(D) TransgenicmRNAexpression in Vk*MYCmice. Splenocytes from6- to 8-week-oldWTandVk*MYCmice have been assayed onday 0 () or after culturing for 4
days in the presence of LPS (+) to induce PC differentiation. Total RNA from various transgenic tissues was isolated and probed for human MYC. As positive and
negative controls, RNA from humanmyeloma cell lines with (SKMM2) or without (U266)MYC rearrangements was assayed. As a loading control, the 28S rRNA is
shown in the lower panel.hadmultiple spikes. By 50weeks, 80%of Vk*MYC and only 25%
of WT mice had M-spikes. Furthermore, by 80 weeks, although
70% of WT mice had developed small M-spikes as expected
(Radl and Hollander, 1974; van den Akker et al., 1988), they se-
creted five times less IgG than age-matched Vk*MYC mice, as
measured by ELISA (median serum IgG 3.25 versus 15.33 g/l)
(Figure 2E). Further isotype-specific ELISA experiments demon-
strated that the most commonly elevated Ig isotypes in the
serum of 70-week-old Vk*MYC mice are IgG1 (median 9.1 g/l
versus 0.49 in WT mice) and IgG3 (1.3 versus 0.39) (Figure S3).
Two of the mice developed type I cryoglobulinemia, a complica-
tion of monoclonal gammopathy (data not shown) (Brouet et al.,
1974). The monoclonal gammopathy serves as a useful tumor-
specificmarker that we used in transplant experiments to assess
the reconstitution of the tumor clone in recipient mice. The
M-spike could be detected in multiple syngeneic mice serially
transplanted with BM mononuclear cells from Vk*MYC mice,
starting as early as 4 weeks posttransplant, indicating the tumor-
igenic nature of these cells (Figure 2F).PCs in Vk*MYC Mice Have Undergone SHM and
Reverted the Engineered Stop Codon
It is well established that long-lived antibody-secreting PCs have
been selected in the GC and have acquired somatic mutations
of their Ig genes (Jacob et al., 1991; MacLennan, 1991). Single
colony sequencing of the VDJ fragment of the heavy chain locus
from Vk*MYC CD138-selected tumor PCs showed evidence of
SHM in every colony, with a median of 2.6% mutations in the
VH gene (Table 1) consistent with the reported range (2%–
4.6%) observed following immunization with NP-immune anti-
gen (Driver et al., 2001). As in human MM, we found no evidence
of intraclonal heterogeneity, indicating that the tumor cells are
no longer subject to ongoing SHM. Interestingly, we found that
the number of clones (identified by the specific VH gene used)
present in a mouse correlated with the number of Ig spikes ob-
served by SPEP (data not shown). This suggests that activation
of the transgene in separate GC cells led to the expansion of
independent PC clones. Single colony sequencing of the trans-
genic locus from CD138-selected Vk*MYC PCs indicated that
Cancer Cell 13, 167–180, February 2008 ª2008 Elsevier Inc. 169
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Mice
(A) BM sections from 18-month-old WT and
Vk*MYC mice were double stained with H&E,
MYC/CD138, and Ki67/CD138. Arrowhead indi-
cates a rare Ki67+ PC. All images are of the
same magnification, and scale bar is shown.
(B) Nucleated BM cells from spleen and BM of
age-matched WT and Vk*MYC mice were ana-
lyzed by FCM. Numbers represent percentage of
cells within each gate.
(C) SPEP was performed on a representative WT
and a Vk*MYCmouse serially bled at the indicated
weeks. The position of the albumin is indicated,
and brackets show the different globulin com-
ponents of the serum. Arrowhead emphasizes
M-spike in Vk*MYC mouse.
(D) Incidence of spikes over time (weeks) in a co-
hort of 40 WT, 60 Vk*MYC, 15 WT immunized,
and 15 Vk*MYC-immunized mice.
(E) Total levels of serum IgG (g/l) in 70-week-old
WT (n = 14) and Vk*MYC (n = 28) mice, measured
by ELISA. Median is 3.22 and 15.33 g/l, respec-
tively (p < 0.0001).
(F) Comigration of M-spike (red arrow) detected
by SPEP on a donor Vk*MYCmouse and two inde-
pendent sets of recipient mice following a first (P1)
and second (P2) serial transplant of BM mononu-
clear cells. Flow cytometry detects CD138+B220
PCs in the BM of P1 recipient mice at the time of
second transplant (right). Representative results
of three independent sets of transplants are
shown.
organ damage, which is a defining crite-
rion for human MM (International Mye-
loma Working Group, 2003). The median
hemoglobin concentration at necropsy
was significantly lower in Vk*MYC mice
than in WT age-matched controls
(10.05 g/dl compared to 13.8 g/dl in WT
mice), indicating anemia (Figure 3A). In
asymptomatic mice, the presence of ane-
mia correlated closely with the presence
of a large M-spike on SPEP. Serum Igsmutations had targeted the transgenic Vk region (at an average
rate of 2.4%, similar to that seen at the endogenous VDJ locus)
and reverted the engineered stop codon. Because multiple cop-
ies of the transgene are expressed, not every colony showed re-
version of the stop codon. However, we conclude that reversion
has occurred in every PC since they all expressed MYC by IHC
(Figure 2A). No mutations were found in theMYC exons that are
separated from the Vk exon by a 2495 bp Jk5 intron, and there-
fore are not expected to be targeted by SHM (Pasqualucci et al.,
2001). These data indicate that, in addition to the IgH variable
region, the SHMmachinery had also targeted the transgenic locus
leading to the activation of MYC expression in post-GC PCs.
Target Organ Damage in Vk*MYC Mice
In addition to the BM localized PC expansion and monoclonal
Ig secretion, Vk*MYC mice at necropsy often exhibited target
170 Cancer Cell 13, 167–180, February 2008 ª2008 Elsevier Inc.could be detected in the tubuli and glomeruli of the kidney
from Vk*MYC mice in the form of protein deposition (Figure 3B),
a phenomenon associated with myeloma kidney disease. Dis-
crete bone lytic lesions and vertebral collapse, resulting in hin-
dlimb paralysis, have occasionally been detected in Vk*MYC
mice (Figure 3C) but are uncommon; nevertheless, bone mineral
density analysis (a more objective and quantifiable measure of
bone disease) performed on sex- and age-matched mice
showed that all Vk*MYC mice suffer from lower bone mineral
density (median 0.595 versus 0.727 mg/mm2, p = 0.0016) con-
sistent with diffuse osteoporosis (Figure 3D), the commonest
form of bone disease in MM patients. Furthermore, microCT
analysis of femurs from a cohort of age- and sex-matched
mice demonstrated a significantly decreased trabecular number
per unit area, or density in Vk*MYC mice (median 0.523 versus
1.271 #/mm2, p = 0.0208; Figure 3D). Overall, these data clearly
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(A) Hemoglobin levels in peripheral blood from 20 agedWT (median 13.8 g/dl), 34 Vk*MYC (10.05), and 14 Vk*MYCxEmBCL2 (7.95) mice. The p value is indicated.
(B) Protein deposition in tubuli and glomeruli is evident in H&E-stained kidney sections from Vk*MYCmice, but not inWT control, and an example is highlighted by
an arrowhead. Scale bar is shown.
(C) X-ray on spine and femurs from WT and Vk*MYC mice. White arrows point to evident bone lytic lesions and intervertebral spinal compression in a Vk*MYC
mouse affected by hindlimb paralysis.
(D) Reduced bone mineral density and trabecular number (by microCT) in Vk*MYCmice (n = 5) compared to age- and sex-matched WT mice (n = 3). ± Standard
deviation is indicated.
(E) Response of Vk*MYC mice to clinically active or inactive drugs is shown as variation in M-spike intensity over time after the indicated weeks of treatment,
compared to baseline levels (100%). Error bars indicate standard deviation.
(F) Overall survival in days of a cohort of 94 WT, 15 WT immunized, 122 Vk*MYC, 15 Vk*MYC-immunized, 24 EmBCL2, and 25 Vk*MYCxEmBCL2 mice. Median
survival in days and p values are shown.
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and clinical features of human MM.
Chemotherapy Sensitivity in Vk*MYC Mice Mirrors
Clinical Activity in Human MM
To determine the response of Vk*MYC mice to commonly
employed chemotherapies in human MM, we selected mice
with evidence of significant monoclonal Ig gammopathies (>15
g/l). These mice were treated either with drugs that are known
to be clinically active in human MM (Alexanian et al., 1986; Berg-
sagel et al., 1962; Richardson et al., 2003) or with drugs that have
shown little benefit in MM. Profound and statistically significant
reductions in M-spike levels (an established surrogate biomarker
for MM disease burden) were observed in the mice treated
with melphalan, dexamethasone, and bortezomib (Figure 3E).
In contrast, mice treatedwith vehicle alone continued to increase
their monoclonal paraproteins during the same treatment
period. Despite the occasional complete disappearance of the
M-spike on SPEP, responses to all three drugs were transient,
as only oncecycle of eachdrugwasadministered. Vincristine, hy-
droxyurea, and fludarabine were also given at either well-estab-
lisheddoses, or at concentrations limitedbymyelotoxicity.Noac-
tivity was observed with these drugs (Figure 3E), consistent with
what has been reported in human clinical trials when used as sin-
gle agents (Davis, 1964; Jackson et al., 1985; Kraut et al., 1990).
Despite developing clinical complications, the majority of
Vk*MYC had an indolent disease course, similar to patients
with MM, and lived almost 2 years, although with a significant
shorter median survival of 661 days, compared to 954 days
of WT mice (Figure 3F, compare WT to Vk*MYC, p < 0.0001).
All of the 122 aged Vk*MYC mice developed a slowly pro-
gressive MM that remained confined to the BM in 52% of
them (63/122). As in some human MM patients (Allen and Cole-
man, 1990), 33% of transgenic mice (40/122) progressed to
a clonally related, proliferative, extramedullary plasmacytoma
(PCT), most commonly B220/CD138+ or occasionally B220+/
CD138int, that spread to spleen, lymph nodes, and the perito-
neal cavity with ascites (Figure S4 and Table 1). The remaining
15% of Vk*MYC mice (18/122), at about 18 months of age de-
veloped a spontaneous B cell lymphoma, MYC negative by
IHC, clonally unrelated by VDJ sequencing to the MM clone,
and similar to the one seen in WT controls (Figure S5 and
data not shown). Interestingly, 2/122 transgenic mice developed
a very aggressive, highly proliferative, isotype class-switched,
somatically mutated, MYC+, BCL6+ Burkitt’s lymphoma (BL)
that invaded multiple organs (kidney, liver, and lung) and infil-
trated in the BM, displacing the PCs and causing a remarkably
rapid disappearance of the M-spike from the serum (Figure S5).
In both these tumors we have identified reversion of the engi-
neered stop codon at the transgenic locus, indicating that
activation of MYC by SHM can also induce BL (Table 1). Alto-
gether, these results show that sporadic activation of a
MYC transgene in GCs results in tumors that faithfully recapit-
ulate the human diseases in which MYC is dysregulated: BL
and MM.
Secondary Events Enable Extramedullary PC Expansion
The survival of long-lived BM PCs is critically dependent on the
presence of specific cytokines present at high concentration inthe BM microenvironment (Moser et al., 2006; O’Connor et al.,
2004). In human MM the growth of malignant PCs is usually re-
stricted to the BM; however, occasional extramedullary dissem-
ination occurs with advanced stages of the disease. Most com-
monly, clonal PCs in Vk*MYC mice accumulated exclusively in
theBMand could not be detected above the normal range in sec-
ondary lymphoid organs (Figures 2B and 4A). We hypothesized
that, by providing a strong antiapoptotic signal, PCs in Vk*MYC
mice could, as in advancedMM, become independent of the sur-
vival signal from the BMmicroenvironment. We crossed Vk*MYC
with EmBCL2 mice and monitored them by SPEP for signs of
monoclonal PC expansion and tumor development. As previ-
ously reported (Strasser et al., 1991), EmBCL2 mice developed
a benign polyclonal B cell and PC expansion and remained
negative for M-spikes by SPEP (Figure 4), never progressing to
a malignant condition during the observation time. In contrast,
all 25 double transgenic mice analyzed, starting at 30 weeks of
age, developed an aggressive extramedullary monoclonal PCT
with infiltration of spleen and lymph nodes (Figure 4A), resulting
in a significantly reduced overall survival (median survival 337
days, compared to 661 days in single Vk*MYC transgenic [p <
0.0001] and 494 days in single EmBCL2 mice [p < 0.0001])
(Figure 3F). Although the aggressive course, localization, and im-
munophenotype of these tumors resemble those of the iMyc/
Bcl-XL mice (Cheung et al., 2004), they differ, as they clearly
have a post-GC origin having undergone SHM (Table 1).
Immunization Induced Antigen-Specific MM
We hypothesized that the expression of the transgene in
Vk*MYC mice could be induced by the activation of SHM during
T cell-dependent antigen response. We thus immunized 15 6- to
8-week-old WT and Vk*MYC mice (without M-spike) with NP-
CGG, and following secondary immunization, we found that
none of the WT, but 2/8 of the Vk*MYC mice, had developed
M-spikes that were specific for NP by eastern blot (Figure 5A).
Following their initial and single round of immunization, Vk*MYC
mice showed an overall spike incidence (Figure 2D) indistin-
guishable from that of nonimmunized mice; however, their over-
all survival was slightly shorter (median 594 versus 661 days,
p = 0.034) (Figure 3F). This shorter survival was associated
with an increased incidence of progression to extramedullary
PCT (77% of Vk*MYC-immunized versus 33% in unimmunized
mice; Figure 4A), suggesting that the immunization in complete
Freund’s adjuvant may have increased the pool of MYC-
expressing cells amenable to the acquisition of secondary muta-
tions. The molecular signature of the NP immune response has
been well characterized and includes the use of the Ig-lambda
light chain, and the use of VH gene J558 186.2 with selection
of the characteristic W to L mutation at position 33 (McHeyzer-
Williams et al., 1993; Weiss and Rajewsky, 1990). RT-PCR was
performed on total BM cells from 11 Vk*MYC-immunized mice,
and overexpression of the Ig lambda gene was detected in three
of them (data not shown). VDJ sequence analysis on two of these
three mice identified the classic signature (VH J558 186.2 with
W33L) of the NP immune response (Table 1). Therefore, our
data indicate that at least 3/15 immunized mice developed NP-
reactive tumors more than 1 year after immunization. In one
case (Vk*MYC24 #44), extensive intraclonal heterogeneity was
noted (Table 1).
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(A) Spleen sections from aged WT, EmBCL2, Vk*MYC, Vk*MYC-immunized, and Vk*MYCxEmBCL2 mice were stained with anti-CD138 antibody to identify PCs.
In the lower panel is shown flow cytometric analysis on the same tissues. Numbers represent cell percentage within each gate. All images are of the same
magnification, and scale bar is shown. A zoomed-in insert of CD138+ PCs is shown.
(B) SPEP identified pronounced M-spikes in Vk*MYC, Vk*MYC-immunized, and Vk*MYCxEmBCL2 mice, but not in WT or EmBCL2.AID Is Required for the Development of MM
in Vk*MYC Mice
AID has been identified as a key enzyme required for the SHM
process, as B cells from AID knockout mice fail to acquire
SHM (Muramatsu et al., 2000). We crossed Vk*MYC mice with
AIDnull mice to test if SHM was responsible for the activation of
the transgene observed in the Vk*MYC mice and for MM devel-
opment. A cohort of 50-week-old sibling AIDnull (16 mice)
Vk*MYCxAIDhet (17 mice) and Vk*MYCxAIDnull (18 mice) were
bled and the sera analyzed by SPEP. Similar to Vk*MYC mice,
1-year-old Vk*MYCxAIDhet showed one or more M-spikes; how-
ever, none of the Vk*MYCxAIDnull or AIDnull mice developed
M-spikes (Figure 5B and data not shown). Finally, BM sections
from 50-week-old Vk*MYCxAIDnull mice double stained with
MYC- and CD138-specific antibodies showed dramatically
fewer PCs and absence of MYC-positive PCs, demonstrating
that AID expression and SHM are required for MYC activation
and PC expansion in Vk*MYC mice (Figure 5C).
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Activation of theMYC Pathway
Given the remarkable resemblance of wild-type C57BL/6 mice to
human monoclonal gammopathy of undetermined significance
(MGUS) andVk*MYCmice to humanMM,wedecided to further as-
sess the potential role of MYC activation in human MGUS-to-MM
progression. Specifically, we assessed the difference in gene ex-
pressionprofilebetweenMMUSandMMusinggenesetenrichment
analysis (GSEA) (Subramanianetal.,2005).GSEAisacomputational
method that determines whether an a priori defined set of genes
(gene sets that are either experimentally derived from previously
published studies, or curated from various databases, and stored
in theMSigDBdatabase) shows statistically significant, concordant
differencesbetweentwobiological states (in thiscaseMGUSversus
MM). The matching uses statistical methods to determine if genes
from the gene sets contained within MSigDB are overrepresented
in the genes over- or underexpressed in MGUS compared to MM,
and if so whether this could have occurred by chance by using
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Myeloma Induced by Activation of MYC TransgeneFigure 5. MM in Vk*MYC Mice Are AID Dependent and Can Be Induced by Immunization in an Antigen-Specific Manner
(A) Sera collected from nonimmunized 50-week-old Vk*MYC mice, and from Vk*MYC mice 2 weeks after secondary NP immunization, were analyzed by SPEP
(top panel). In parallel, SPEP gel was blotted onto a filter preincubated with NP-biotinylated to identify NP reactive Igs (lower panel). Brackets identify M-spikes;
arrowhead points to NP-specific ones.
(B) Sera from 50-week-old Vk*MYCxAIDhet and Vk*MYCxAIDnull mice were analyzed by SPEP.
(C) BM section from 50-week-old Vk*MYCxAIDnull mouse double stained with MYC/CD138-specific antibodies. Only few PCs are detected, all MYC negative.
Scale bar is shown.permutation testing. As an internal control, significant enrichment of
several relevantMMrelatedgenesets (e.g., genesoverexpressed in
MM versus amyloidosis, which is biologically similar to MGUS) and
ofproliferation-associatedgenesets, awell-establishedphenotypic
difference betweenMM andMGUS (Boccadoro et al., 1984; Witzig
et al., 1999) was observed using this technique. Strikingly, seven of
eight gene sets directly associatedwithMYC activation (froma total
of 687 gene sets) were significantly enriched in MM (Figure 6A).
Next,wederivedaMYCgenesignature, usingaset of recently iden-
tified ‘‘first neighbors’’ to MYC in a B cell-specific transcriptional
network and validated as direct DNA-binding targets of MYC by
chromatin immunoprecipitation (Bassoet al., 2005). In two indepen-
dent data sets, bothMYC expression and the MYC signature were
notpresent innormalPCs, rarelyweaklypresent inMGUS,butpres-
ent in themajority ofMM (Figure 6andFigureS6). This indicates that
the elevatedMYCmRNA expression is functionally associatedwith
the expected MYC transcriptional effect. In other related B cell
malignancies, the MYC signature was strongly expressed only in
BL, which is characterized byMYC translocation to the Ig loci, but
was absent in normal peripheral blood B cells, chronic lymphocytic
leukemia (CLL), andWaldenstrommacroglobulinemia (WM). Ingen-
eral, the highest MYC expression was seen in the samples with
strong MYC signature, and both correlate loosely with proliferation
(r2 = 0.3) (Figure 6B). Of interest, some MM samples had MYC
expressionat the impressive levels seen inBL.Thesemay represent
MMsampleswithMYC translocations,whichhavebeen reported to
be present in about 15% of MM (Figure 6C). A MYC index derived
from the median expression of genes that form the MYC signature
was a more robust discriminator between MM and MGUS (p <
0.0001) than MYC expression itself, which had more variable
expression even in MGUS (Figure 6C). All in all, these data suggest
that MYC activation is a common and possibly critical event in
human MGUS-to-MM progression.
DISCUSSION
A role for AID in tumorigenesis has long been suspected, since
mistargeted switch recombination and somatic hypermutation,both processes mediated by AID, are implicated in chromosome
translocations or oncogene mutations in B cells (Okazaki et al.,
2007). An indirect link between AID and translocations has
been established by the finding that AIDnull IL6 transgenic mice
failed to develop IGH/MYC translocations (Ramiro et al., 2004).
Also, loss of AID in EmMYCmice induced a change in tumor phe-
notype from B cell to pre-B cell lymphoma, suggesting that AID
mutational activity contributes to B cell but not pre-B lymphomas
(Kotani et al., 2007). Our data indicate an oncogenic role for AID
in post-GC neoplasms. Specifically, we show that in the absence
of AID C57BL/6 WTmice fail to develop the post-GC gammopa-
thies that spontaneously occur at high incidence in this strain of
mice. In addition, we show that it is possible to direct AID activity
to an exogenous substrate (Vk*MYC transgene) to activate an
oncogene (MYC) and drive post-GC tumorigenesis.
Vk*MYC Construct as a Tool for Modeling Post-GC
Malignancies in Mice
MYC has long been associated with GC and post-GC B cell neo-
plasms, and here we demonstrate the causal role ofMYC in their
development by successfully modelingMYC-driven, GC-derived
lymphoid proliferation in mice. We report the generation of a
mouse model in which activation of an oncogene is both spo-
radic and initiated by SHM, whose off-target activity has been
implicated in oncogene activation in B cell neoplasia. This patho-
genetic fidelity results in the phenotypic fidelity of post-GC tu-
mors that recapitulate human disease displaying clinical and
therapeutic fidelity.
MYC Activation as a Progression Event
from MGUS to MM
Although MYC dysregulation has been implicated as a primary
event in human BL and a progression event in human MM, out
of 122 Vk*MYC mice analyzed, only two developed BL, while
they all developedMM. It is possible that the genetic background
of Vk*MYC mice may account for their propensity to develop
MM. We specifically chose the C57BL/6 mouse strain to gener-
ate the Vk- and Vk*MYC transgenic mice because of their high
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Associated with Overexpression of MYC
and MYC Target Genes
(A) All the gene sets directly associated with MYC
activation (highlighted in red), cell cycle, and pro-
liferation (highlighted in blue) and relevant to
previous experiment comparing MM to MGUS
(highlighted in gray) available in the MSigDB data-
base utilized for GSEA, regardless of whether they
are significantly enriched, are selected and pre-
sented in the table. These are extracted from the
complete list of gene sets (n = 687) used for the
analysis (see Table S1). The overall rank of these
gene sets in relation to the complete list is also
presented. Among these gene sets, those in bold
and above the horizontal line are significantly
enriched (p < 0.05 and q < 0.05).
(B) This heatmap represents the expression of
genes constituting the MYC signature in normal
peripheral blood B cells (BC), chronic lymphocytic
leukemia (CLL), Burkitt’s lymphoma (BL), MGUS,
MM, Waldenstrom macroglobulinemia (WM), and
normal plasma cells (PC). The samples are ar-
ranged by diagnosis and ascending MYC index.
On the heatmap, red indicates overexpression,
blue indicates underexpression, and white
indicates median expression. The scaling of the
heatmap is indicated by the color bar underneath
the heatmap.
(C)MYC expression and the MYC index are repre-
sented as a dot plot according to the different cell/
disease type shown in Figure 6B. The horizontal
red line represents the mean value. The standard
deviation (SD) is indicated.
(MGUS), which affects 3% of adults over
the age of 50 and progresses to fully ma-
lignant MM at a rate of 1% per year (Kyle
et al., 2006). Although several genetic le-
sions have been implicated in MM dis-
ease progression, the genetic basis for
the malignant switch from MGUS to MM
remains to be identified. RAS mutations
have been identified only rarely in
MGUS but are present in 30% of newly
diagnosed MM, with an increasing fre-
quency with advanced disease, and
have been proposed to induce MGUS-
to-MM progression (Rasmussen et al.,
2005).
Our results in theVk*MYCmousemodel
prompted us to investigate further the role
of MYC dysregulation in the transition
from MGUS to MM in humans. We foundincidence of spontaneous monoclonal gammopathy with age
(van den Akker et al., 1988). We postulate that in this specific
strain of miceMYC dysregulation may act as secondary genetic
event driving the progression of a benign monoclonal gammop-
athy to a fully malignant MM.
HumanMM is preceded by a common premalignant condition
called monoclonal gammopathy of undetermined significance
176 Cancer Cell 13, 167–180, February 2008 ª2008 Elsevier Inc.that, compared to MGUS, the majority of MM expresses, as
expected, higher levels of genes associated with proliferation
(Boccadoro et al., 1984;Witzig et al., 1999), but also higher levels
ofMYC,which can reach in somecases the levels seen in BL, and
which correlate with higher levels of known MYC target genes
(Basso et al., 2005). Although these findings per se do not prove
a causative role for MYC in the progression of MGUS to MM in
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Myeloma Induced by Activation of MYC Transgenehuman, our results in the Vk*MYCmice, whereMYC activation in
a mouse prone to MGUS leads to MM, suggests that MYC is
capable of driving the same progression in human. We propose
a mechanism in which the primary initiating genetic event, which
occurs in aGCBcell (IgH translocation or hyperdiploidy), leads to
dysregulation of a cyclin D protein, overcoming the G1 cell cycle
checkpoint and resulting in MGUS (Bergsagel et al., 2005).MYC
activation occurring as a secondary event further increases cell
proliferation by promoting transit to S phase through initiation of
DNA origin of replication (Dominguez-Sola et al., 2007) (Figure 7).
MYC dysregulation in MM can occur in cis by chromosomal
rearrangements that are found in 40% of advanced patients by
metaphase FISH (Shou et al., 2000), 15% of newly diagnosed
MM, but only 3% (2/65) of MGUS by interphase FISH (Avet-
Loiseau et al., 2001). Although it is possible that a more compre-
hensive and detailed analysis of the MYC locus may reveal a
higher incidence of complexMYC translocations for MM patients
in whom metaphases are not available, we also postulate that
MYC activation may occur by dysregulated trans-activation
through the transcriptional activity of presently uncharacterized
factors. In any case, the discovery that MYC is implicated in the
transition fromMGUS to MM, based on our mouse study, re-em-
phasizes the validity of mouse models not simply as validation
tools to assess the contribution of known mutations to cancer,
or as drug testing tools, but also as discovery tools that allow
the identification of important genetic pathways in human cancer.
Vk*MYC Mice as Model for Human Multiple Myeloma
While it is widely believed that no single mouse model is capable
of reproducing all facets of a specific human cancer, the Vk*MYC
Figure 7. Stepwise Dysregulation of Early Cell Cycle Checkpoints
during MGUS and MM Evolution
An early event in MM is overexpression of a cyclin D gene as the result of a pri-
marymutation (translocation or hyperdiploidy). Cyclin D overexpression in PCs
presumably enables these cells to autonomously overcome the early G0G1
checkpoint, contributing to limited clonal PC expansion (MGUS). Overexpres-
sion of MYC is one secondary event that may eliminate remaining cell cycle
constraints. Significantly, it was recently demonstrated that MYC is directly
involved in DNA replication, binding and activating DNA replicative origins and
regulating progression of cells into S phase (Dominguez-Sola et al., 2007).
Therefore, we propose that MYC dysregulation is an important progression
event betweenMGUS andMM andmechanistically circumvents cell cycle con-
straints remaining in cells overexpressing cyclin D by promoting transit into
the DNA synthesis S phase through increased DNA replicative origin activity.mice fulfill many of the biologic and genetic criteria of an ideal
mouse model, showing a high degree of homology to the clinical
phenotype of human MM. First, the Vk*MYC model relies upon
a sporadic, yet precisely timed, physiologic mechanism for on-
cogenic activation, providing a model of tumorigenesis with
high penetrance. Reversion of the engineered stop codon
SPEP and VDJ sequencing studies indicate that the tumor is in-
deed clonal, and post-GC in origin, having undergone SHM.
Other transgenic mouse models of MM have not convincingly
shown evidence of SHM (Table S2). The malignant phenotype
of Vk*MYC MM cells is further demonstrated by their successful
transplantation into syngeneic recipient mice (Figure 2F). Sec-
ond, the Vk*MYC mice display histologic and immunopheno-
typic concordance with human MM and are perfectly suited to
the study of the aspects of tumor biology that require an intact
and native host-tumor environment. No immunocompetent
transgenic mouse model of MM has shown BM-restricted PC
growth, but more typically they have displayed an aggressive
extramedullary PC proliferation (Table S2). Third, the phenotype
in the Vk*MYC mice depends on the activation of MYC that, al-
though is not thought to be a primary genetic event in MM, is
strongly implicated in the pathogenesis of human MM, where
we propose it promotes the progression fromMGUS toMM. Fur-
ther analysis will determine the extent to which the Vk*MYCmice
recapitulate the genetic complexity and heterogeneity of the
human disease. Fourth, Vk*MYC mice share all of the important
clinical features present in human MM. In contrast to existing
models, themonoclonal paraproteins in Vk*MYCmice are all iso-
type class switched and secreted at a level observed in human
disease (Table S2). Vk*MYC mice have an indolent course that
slowly but invariably leads to end organ damage such as renal
dysfunction, bone disease, and anemia. Fifth, while the etiology
ofMYC activation in this model has been engineered, the model
nevertheless relies on environmental factors in the form of anti-
genic stimulation to initiate that activation. Chronic antigenic
stimulation has long been implicated in the development of
MM, and in rare cases the putative antigen has been identified
as a result of exceptionally high titer of reactive Igs against cyto-
megalovirus, HIV, and streptolysin-O (Kohler et al., 1987; Konrad
et al., 1993; Seligmann et al., 1968). Likewise, we were able to
generate antigen-specific MM tumors by immunization, sug-
gesting a novel method for the production of monoclonal anti-
bodies. Sixth, the high degree of biologic and phenotypic similar-
ity between the PCs of Vk*MYC mice and human MM cells likely
explains the therapeutic fidelity that we have demonstrated in
this model. For the preclinical validation of therapeutic agents,
it is critical to have a mouse MM model that demonstrates
both a response to drugs with known activity in the clinic as
well as a lack of response to those with no clinical utility. In con-
clusion, the Vk*MYC model of MM fulfils all of the above criteria
of an ideal mouse model (Table S2) and will be useful for the
study of MM cell biology and genetics in a native environment,
as well as serve as a powerful tool to predict the utility of novel
MM treatment strategies.
EXPERIMENTAL PROCEDURES
For detailed information, please refer to the Supplemental Data.
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All experiments were performed under The Mayo Foundation Institutional
Animal Care and Use Committee (IACUC) approval and conformed to all the
regulatory standards. The linearized Vk*MYC and Vk-MYC constructs were
microinjected into pure C57BL/6J fertilized eggs (SKI/Cornell Transgenic
Mouse Core, New York).
For survival studies, mice were aged until they showed evident signs of
tumor and/or discomfort and then sacrificed. Sibling control mice were sacri-
ficed at the same time or allowed to age further. Necropsy was performed to
assess the presence of phenotypic abnormalities. Statistical analysis was per-
formed on the Prism software (GraphPad Software Inc.); survival curves were
generated using the Kaplan-Meyer method and were compared using a log-
rank test. EmBCL2 mice in pure C57BL/6 background were purchased from
The Jackson Laboratories. AIDnull mice in pure C57BL/6 background were
a gift from Dr. M. Nussenzweig.
Flow Cytometry
The following antibodies were used alone or in combinations on single-cell
suspensions: CD3 (17A2), CD19 (1D3), Kappa (187.1), CD43 (S7), B220
(RA3-6B2), IgM (II/41), IgD (11-26c.2a), and CD138 (281-2) (all BD Pharmin-
gen). Data were acquired on a CyanADP (Dako Cytomation) instrument and
analyzed with FlowJo software (Tree Star).
Immunizations
Eight- to sixteen-week-old mice (eight Vk*MYC and four WT controls) were
immunized intraperitoneally with 50 mg NP-CGG (Biosearch Technologies)
emulsified in complete Freund’s adjuvant (Sigma) and boosted 6 weeks later
with same amount of antigen in incomplete Freund’s adjuvant (Sigma).
Gene Expression Cohort
A Mayo cohort of 101 MM, 22 MGUS, 14 Waldenstrom Macroglobulinemia
(WM), 7 Chronic Lymphocytic Leukemia (CLL), 6 normal donors of peripheral
blood B cells (BC), and 15 normal donors of plasma cells (PC) were included
in the study. All patients donated samples following informed consent. The
study was approved by the Mayo Foundation Institution Review Board. RNA
from purified tumor population was extracted and gene expression profiling
performed using the Affymetrix U133A gene chip.
Electronic Availability of the Data
The gene expression data have been previously published (Gene Expression
Omnibus [GEO] accession number GSE6477). Another gene expression data
set comprised of 22 PC, 43 MGUS, 351 MM, and 44 human myeloma cell lines
performed on the U133plus2.0 gene chip was also analyzed (GEO accession
numbers GSE2658 and GSE 5900). Burkitt’s lymphoma gene expression data
generated with the U133A gene chip were extracted from a data set published
in GEO (accession number GSE4475).
Supplemental Data
The Supplemental Data include Supplemental Experimental Procedures, six
supplemental figures, and two supplemental tables and can be found with
this article online at http://www.cancercell.org/cgi/content/full/13/2/167/
DC1/.
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